Condensed Consolidated Balance Sheets (USD $) In Thousands	Jun. 30, 2011	Dec. 31, 2010
Current assets:
Cash and cash equivalents	$ 168,743	$ 226,340
Marketable securities, current	353,799	322,973
Restricted cash	0	31,910
Receivable from collaboration partners	50,879	51,412
Prepaid expenses and other current assets	14,897	12,549
Total current assets	588,318	645,184
Marketable securities, non-current	28,053	28,555
Property and equipment, net	18,570	10,822
Intangible assets - in-process research and development	438,800	438,800
Goodwill	193,675	193,675
Other assets	18,026	35,599
Total assets	1,285,442	1,352,635
Current liabilities:
Accounts payable	23	16
Accrued liabilities	15,273	16,866
Accrued clinical trials and related expenses	18,890	15,093
Accrued compensation	8,199	9,251
Lease termination exit costs, Current	5,465	0
Escrow account liability	0	31,634
Total current liabilities	47,850	72,860
Convertible senior notes due 2016	157,645	152,701
Liability for contingent consideration	270,708	253,458
Deferred tax liability	157,090	157,090
Other liabilities	24,561	18,952
Lease termination exit costs, non-current	7,622	0
Commitments and contingencies
Stockholders' equity:
Common stock	63	63
Additional paid-in capital	1,264,046	1,238,204
Receivable from stock option exercises	(10)	(6)
Accumulated other comprehensive loss	(1,034)	(1,291)
Accumulated deficit	(643,099)	(539,396)
Total stockholders' equity	619,966	697,574
Total liabilities and stockholders' equity	$ 1,285,442	$ 1,352,635